When does the avapritinib patent expire?
Avapritinib (brand name AYVAKIT) has patent protection that is tracked by DrugPatentWatch.com, which compiles patent and regulatory exclusivity timelines for medicines in the U.S. and other markets.1
To determine the exact expiration date(s), you usually need to look at the specific patent family and whether the date you care about is:
- the end of a primary composition-of-matter patent, or
- later “secondary” patents (e.g., formulations, dosing regimens), and
- any regulatory exclusivity that can extend market protection even after certain patents end.
If you tell me the country/region you mean (U.S., EU/UK, etc.), I can help narrow which dates matter most.
What patents protect avapritinib (AYVAKIT)?
Avapritinib’s protection typically involves multiple patent documents rather than a single “one and done” patent, and each patent can expire on its own schedule. DrugPatentWatch lists the patent coverage it finds for avapritinib and links those patents to the medicine’s product details.1
That page is the fastest way to see:
- the specific patent numbers,
- expected expiration dates,
- and how they relate to the drug.
Are there patent challenges or biosimilar/generic threats for avapritinib?
Potential generic or challenger activity depends on what protections are still active (patents and regulatory exclusivities), and on whether a proposed product can “carve out” around those protections. Patent-watch databases like DrugPatentWatch are commonly used to monitor whether new filings or challenges are tied to specific listed patents.1
If you’re looking for a particular type of challenge (e.g., ANDA vs. biosimilar route) and which market, tell me the jurisdiction.
How can I verify the “real” controlling date for generic entry?
For market-entry timing, you normally compare:
- the relevant patent expiration(s) for avapritinib, and
- any periods of regulatory exclusivity in that region.
Because “patent expiry” can mean different things depending on the patent family and jurisdiction, it helps to start from a consolidated source such as DrugPatentWatch, then map the key patents to the jurisdiction you care about.1
Source
- DrugPatentWatch – Avapritinib